Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Income (2016 - 2025)

Ani Pharmaceuticals' Operating Income history spans 14 years, with the latest figure at $34.8 million for Q4 2025.

  • For Q4 2025, Operating Income rose 894.13% year-over-year to $34.8 million; the TTM value through Dec 2025 reached $111.1 million, up 18922.77%, while the annual FY2025 figure was $111.1 million, 18922.77% up from the prior year.
  • Operating Income for Q4 2025 was $34.8 million at Ani Pharmaceuticals, down from $36.2 million in the prior quarter.
  • Across five years, Operating Income topped out at $36.2 million in Q3 2025 and bottomed at -$23.7 million in Q4 2021.
  • The 5-year median for Operating Income is $4.1 million (2021), against an average of $4.2 million.
  • The largest annual shift saw Operating Income crashed 7267.07% in 2021 before it surged 894.13% in 2025.
  • A 5-year view of Operating Income shows it stood at -$23.7 million in 2021, then surged by 107.67% to $1.8 million in 2022, then soared by 269.56% to $6.7 million in 2023, then tumbled by 165.09% to -$4.4 million in 2024, then soared by 894.13% to $34.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Operating Income are $34.8 million (Q4 2025), $36.2 million (Q3 2025), and $13.9 million (Q2 2025).